Our Business

Global Reporting Frameworks

Pfizer continues to evaluate our approach to non-financial reporting, including adherence to several existing, globally recognized external frameworks.

These include the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB) and the International Integrated Reporting Council (IIRC). We have relied on elements of each framework in developing this year's Annual Review while adhering to none in its entirety. We have included a GRI Reference Table in this Annual Review as a reference tool to help readers more readily locate relevant information across Pfizer's web-based resources.

Download GRI Reference Table

GRI Table (PDF 0.17mb)

We also take into account elements of other Environment, Social and Governance (ESG) indices and sustainability indicators, in particular the Access to Medicines Index and the United Nations (UN) Sustainable Development Goals (SDGs).

GRI Reference Table

GRI Indicator Description Reference Alignment with the UN SDGs1
Strategy and Analysis
G4-1 CEO/Chair Statement CEO Letter — To Our Stakeholders  
Organizational Profile
G4-3 Company name Pfizer Inc.  
G4-4 Company brand, products and services CEO Letter  
G4-5 Location of headquarters New York, New York (U.S.)  
G4-6 Main countries of operation Global Commercial Businesses  
G4-8 Markets served (e.g. sectors, customers) Our Business  
G4-9 Scale of company (e.g. employees, sales) CEO Letter  
G4-10 Employee profile Pfizer Careers Goal 8
G4-12 Description of company supply chain Our Business  
G4-14 Precautionary approach / principle Pfizer manages and reports on our risks and impacts in consideration of the precautionary principle.  
Identified Material Aspects and Boundaries
G4-17 Entities included in financial statements About this Review  
G4-18 Process for defining report content About this Review  
G4-19 Material issues / aspects identified About this Review  
G4-23 Significant changes in scope / boundaries Pfizer footprint and capabilities grew with the acquisition of AstraZeneca's anti-infectives portfolio, Bamboo Therapeutics, BIND Therapeutics, and Medivation, Inc. which are included in the 2016 Annual Review  
Stakeholder Engagement
G4-24 Stakeholders engaged CEO Letter  
G4-26 Approach to stakeholder engagement Partnerships  
Report Profile
G4-28 Reporting period About this Review  
G4-29 Date of previous report See Previous Annual Review  
G4-30 Reporting cycle About this Review  
G4-31 Reporting contact point Chris Gray, Senior Director, Corporate Responsibility  
G4-32 In accordance option chosen GRI Reference Table  
Governance
G4-34 Governance structure Governance and Ethics  
G4-37 Governance and stakeholder engagement Corporate Governance FAQs

Goal 16

G4-38 Composition of the Board Board of Directors

Goal 5

Goal 16

G4-39 Chair of the Board Board of Directors

Goal 16

G4-40 Nomination of Board Members The Pfizer Board: Board Policies

Goal 5

Goal 16

G4-41 Conflict of interest and the Board The Pfizer Board: Board Policies

Goal 16

Ethics and Integrity
G4-56 Values, principles and codes Pfizer Compliance

Goal 16

Economic
DMA Disclosures on Management Approach SDGs  
G4-EC1 Direct economic value Transforming Delivery of High Quality Products

Goal 2

Goal 5

Goal 7

Goal 8

Goal 9

G4-EC7 Infrastructure investments and services Bringing Resources to Bear to Improve Global Health

Goal 2

Goal 5

Goal 7

Goal 9

Goal 11

G4-EC9 Local supplier spending Transforming Delivery of High Quality Products

Goal 12

Environmental
DMA Disclosures on Management Approach Environment, Health and Safety  
G4-EN8 Total water withdrawal by source Environment, Health and Safety

Goal 6

G4-EN23 Total waste Environment, Health and Safety

Goal 3

Goal 6

Goal 12

G4-EN27 Mitigation of product impacts Environment, Health and Safety

Goal 6

Goal 8

Goal 12

Goal 13

Goal 14

Goal 15

G4-EN33 Supply chain environmental impacts Environment, Health and Safety  
Social: Labor practices and decent work
DMA Disclosures on Management Approach Culture  
G4-LA6 Injuries and work related fatalities Culture

Goal 3

Goal 8

G4-LA9 Employee training Culture

Goal 4

Goal 5

Goal 8

G4-LA10 Employee skills and learning Culture

Goal 8

Social: Human rights
DMA Disclosures on Management Approach Governance and Ethics  
G4-HR2 Human rights training Human Rights Statement  
G4-HR3 Discrimination Culture

Goal 5

Goal 8

Goal 16

Social: Society
DMA Disclosures on Management Approach Governance and Ethics  
G4-SO1 Local community engagement Public Health Impact  
G4-SO2 Impacts on local communities Public Health Impact

Goal 1

Goal 2

G4-SO3 Anti-corruption risk Practical Ethical Sales and Marketing

Goal 16

G4-SO6 Political contributions Corporate and Shareholder Information

Goal 16

Social: Product responsibility
DMA Disclosures on Management Approach

Product Stewardship

How We Conduct Clinical Trials

 
G4-PR1 Health and safety impacts of products Manufacturing and Supply Chain  
G4-PR5 Customer satisfaction Access to Medicines  
G4-PR8 Customer privacy breaches Clinical Trials

Goal 16

  1. Based on a more detailed analysis available on the SDG Compass website.

Close

No Poverty

Close

Zero Hunger

Close

Good Health and Well-Being

We promote holistic solutions to meet the health needs of the underserved while investing in the well-being of the global community.

View all goals

Close

Quality Education

Close

Gender Equality

We seek to empower and mobilize women around the world through partnerships aimed at ensuring access to quality health care, including newborn immunizations and family planning services.

View all goals

Close

Clean Water and Sanitation

Through public-private partnerships like the International Trachoma Initiative, as well as efforts to responsibly manage our water consumption and disposal, we aim to advance public health by improving water supply, sanitation and hygiene.

View all goals

Close

Affordable and Clean Energy

Close

Decent Work and Economic Growth

Close

Industry, Innovation and Infrastructure

We catalyze scientific innovation through cutting-edge research initiatives and unique, results-driven partnerships in order to deliver novel medicines, vaccines and know-how to individuals around the world.

View all goals

Close

Reduced Inequalities

Close

Sustainable Cities and Communities

We promote healthy behavior for people of all ages in urban environments through programs to reduce pollution, promote age-friendly policies and improve health services for those most in need.

View all goals

Close

Responsible Consumption and Production

Throughout the lifecycle of our products, we are working toward reducing our carbon footprint and increasing energy efficiency, decreasing dependence on limited resources and reducing waste.

View all goals

Close

Climate Action

Close

Life Below Water

Close

Life On Land

Close

Peace, Justice and Strong Institutions

Close

Partnerships for the Goals

Through innovative partnerships, including collaborations with non-governmental organizations (NGOs), governments, foundations, social entrepreneurs and colleagues, we seek to fuel creative approaches that accelerate progress and improve health care.

View all goals